Leveraging the Anti-Tumor Activity of the Immune System: Systemic Treatment for Advanced Non-Melanoma Skin Cancers
April 12, 2023
April 13, 2024
This activity is provided by Med Learning Group and AMEDCO.
This program is supported by an independent medical educational grant from Regeneron Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Nursing and Pharmacy learners, view this Learner Notification prior to starting this activity.
This activity is designed to meet the educational needs of global oncologists, dermatologists, Mohs surgeons, and the multidisciplinary care team who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
This enduring activity will increase the target HCP’s understanding of new immune therapies and clinical trial data for treating patients with advanced NMSCs; ability to identify and manage side effects associated with new systemic therapies for treating patients with advanced BCC; and ability to coordinate care and improve outcomes for patients with advanced NMSCs failing or not amenable to surgery or radiation.
After participating in this program, participants will be better able to:
- Evaluate recent immune therapy clinical trials data in the treatment of patients with metastatic or locally advanced non-melanoma skin cancers
- Describe the recognition and management of treatment related adverse events associated with immune checkpoint inhibitor therapy in patients with non-melanoma skin cancers
- Examine the communication, processes and tools that support a multidisciplinary team approach in the management of patients with non-melanoma skin cancers
David M. Miller, MD, PhD, FAAD
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Assistant Professor of Medicine and Dermatology
Massachusetts General Cancer Center
Harvard Medical School
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosures of Conflicts of Interest
- David M. Miller, MD, PhD, FAAD
- Honoraria for Participation on Advisory Boards : Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences and Checkpoint Therapeutics
- Stock: Checkpoint Therapeutics
- Research Funding: Regeneron, Kartos Therapeutics, NeoImmune Tech, Inc, Project Data Sphere, ECOG-ACRIN, American Skin Association.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.